Super User

Super User

Expanded Board and Blue Chip Investors Position Company for Global Reach

Bath, UK, 3 October, 2017. Atlas Genetics Ltd., the ultra-­rapid, point-­of-­care (POC) testing company for women’s and family health, today announced that Jeffrey R. Luber  has been appointed Chief Executive Officer effective 1 October 2017. Dr John Clarkson, current founding CEO, will become Executive Chairman and current chairman, Neil Butler, will remain with the Company as a non-­executive director of the Board.

Mr. Luber joins the Board of Atlas Genetics with broad experience in the life sciences industry, including having held multiple leadership roles in both public and private companies. Most recently, he led the return to growth and sale of Good Start Genetics to Invitae Corp (NYSE: NVTA). In this role, Jeff led the company in new directions, restoring growth to its core business, expanding its reach into consumer markets, and entering into transformative strategic partnerships with Roche Diagnostics and Amazon. Prior to this, Jeff was CEO of EXACT Sciences (NASDAQ: EXAS) where he executed its successful turnaround and strategic transaction with Genzyme Corp.

Dr John Clarkson, founding CEO of Atlas Genetics, said: “We are delighted to welcome Jeff to Atlas Genetics. Jeff’s proven track record and extensive experience in the commercialisation of in vitro diagnostics will be invaluable as we enter the next, exciting phase of growth aimed at improving the diagnosis and treatment of conditions affecting women and families.”

Mr Jeffrey Luber, commented: “I am thrilled to join Atlas Genetics, given the power of its platform, the strength of its board and leadership team, and its experienced investor syndicate. Dr. Clarkson has built a world class team of scientists and engineers who have developed a truly differentiating technology platform in Point of Care testing for broad global markets. As diagnostic testing increasingly becomes more decentralized, I look forward to working with the team to make Atlas the leading global player in POC testing.”

Florent Gros, Managing Director of Novartis Venture Fund and non-­executive director of Atlas Genetics, added: “At Novartis Venture Fund, we seek out novel platforms to address global unmet needs and stellar management to drive innovation and growth. With Point of Care testing expected to grow to 35% by 2020, from less than 1% today, we are thrilled to have Jeff on board and look forward to his leadership through this very exciting next phase of global growth for the company.”

Atlas Genetics’ Investors include Novartis Venture Fund, Johnson & Johnson Innovation -­ JJDC, Inc., Consort Medical plc and China-­based Wondfo Biotech.

Contact details:

Atlas Genetics Ltd: Tel: +44 (0) 1225 717930

Jeff Luber & John Clarkson

FTI Consulting: Tel: +44 (0) 20 3727 1000

Mo Noonan/ Anna Foster

About Atlas Genetics

Atlas Genetics is an in vitro diagnostics company focused on decentralized, near-­patient and point-­of-­care (POC) testing for the benefit of women and families globally. The
Company’s proprietary technology platform is positioned to improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. Rapid turnaround times, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. The io® platform offers a sample-­to-­answer time of 30 minutes, or less, making it possible to carry out infectious disease tests in primary care clinics and physicians’ offices anywhere.

For further information visit www.atlasgenetics.com

Tagged under

CAMBRIDGE, Mass., December 12, 2017 – Atlas Genetics, a rapid, near-patient and point-of-care (POC) testing company, today announced the appointment of industry veteran Marc Jones as Chief Operating Officer (“COO”) and Chief Financial Officer (“CFO”).

In this dual role, Jones will lead Atlas Genetics’ finance and operations functions, as well as new channel development, and he will again partner with Jeffrey Luber, President and Chief Executive officer of Atlas, in key areas influencing strategic direction and execution.

“We are pleased to welcome Marc to the executive team as Atlas transitions from clinical proof of concept to its commercial phase globally,” said Luber. “The healthcare landscape is changing rapidly, with an emerging focus on consumer convenience and rapid testing in decentralized locations. With the Atlas io® platform’s ability to detect disease through a small, desktop instrument, we are poised to leverage these growing trends. Having talent of Marc’s caliber aboard, joining a stellar team of executives, will ensure we are ready to lead in new high-growth mobile/digital and retail health categories. Marc is a visionary executive with a proven track record of successfully guiding healthcare companies in new market categories through important commercial milestones. He has great skill in taking new ideas from concept to execution on time and on budget.”

Jones joins Atlas Genetics from Good Start Genetics, where he served as the COO and CFO. In that role, Jones and Luber raised successive rounds of capital and helped lead the turnaround of the company to record business growth and its ultimate sale to publicly traded Invitae (NYSE:NVTA).Prior to Good Start Genetics, Jones served as the CFO of T2 Biosystems, where he oversaw the company’s successful public offering, raising nearly $100 million in capital, and helped drive the commercialization of the company's first FDA approved IVD product. Previously, Jones held the CFO position at Crashlytics, Ivenix and CHiL Semiconductor. Earlier in his career, he held a number of corporate finance positions ranging from Fortune 50 companies to high-growth startups.

About Atlas Genetics
Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-patient and point-of-care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-to-use, rapid and cost-effective solution for on-demand diagnosis of infectious diseases. Rapid turnaround times, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. The io® platform offers a sample-to-answer time of 30 minutes, or less, making it possible to carry out infectious disease tests in primary care clinics and physicians’ offices anywhere.

Atlas Genetics’investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund.

For further information visit www.atlasgenetics.com.
Contact:
Marc Jones
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-646-847-8573

Tagged under

CAMBRIDGE, Mass. & BATH, United Kingdom, January 5, 2018 – Atlas Genetics, a rapid, near-patient and point-­of-­care (POC) testing company, today announced that it has appointed Stanley Lapidus to the role of independent board member on its Board of Directors.  Lapidus has more than 30 years’ experience in the medical diagnostics industry as a founder, CEO and board member at companies that have dramatically impacted the diagnostics landscape, including his founding of EXACT Sciences Corp. (NASDAQ:EXAS) and, prior to that, Cytyc Corp., which was sold to Hologic Corporation in 2007.

“We are honored to have Stan, a true luminary in biotechnology, join Atlas Genetics as its newest board member,” said Jeff Luber, President and CEO of Atlas. “He comes to Atlas at a pivotal time as we transition from clinical validation of our proprietary platform in POC testing to becoming a commercially disruptive force globally. As one of the most successful leaders, innovators and entrepreneurs in the diagnostics industry, Stan has provided strategic insights to emerging healthcare companies through similar commercial arcs. His counsel will be invaluable as Atlas capitalizes on a quickly changing healthcare landscape where rapid testing and consumer convenience become increasingly paramount. We view his association with Atlas as another indication of the opportunity here and the great things to come.”

Lapidus founded EXACT Sciences and served as its CEO and Chairman until 2006. Since commercial introduction of the company’s Cologuard test for non-invasive, early detection of colorectal cancer, EXACT has been the most rapidly growing company in the history of the diagnostics industry. Prior to EXACT Sciences, Lapidus was founder and CEO of Cytyc Corp prior to its acquisition by Hologic for $6.2 billion. He is the principal inventor of Cytyc’s ThinPrep Pap test, which revolutionized screening for cervical cancer and now accounts for approximately 80% of the world market for cervical cancer screening. Lapidus was also the founder and CEO of SynapDx and Helicos Biosciences.

Currently, Lapidus serves as a director to a number of public and private medical device and diagnostics companies, and he was an instructor at MIT from 2001 to 2017.

Lapidus is a seasoned innovator holding 36 U.S. patents. He was elected as a Fellow of the American Institute of Medical and Biological Engineering in 2013 for his work on the early detection of cancer.

Lapidus graduated from Cooper Union in New York City with a BS degree in electrical engineering.

About Atlas Genetics

Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and point-­of-­care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. Rapid turnaround times, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. The io® platform offers a sample-­to-­answer time of 30 minutes, or less, making it possible to carry out infectious disease tests in primary care clinics and physicians’ offices anywhere.

Atlas Genetics’ investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund.

For further information visit www.atlasgenetics.com.

Contact:

Marc Jones

This email address is being protected from spambots. You need JavaScript enabled to view it.

1-646-847-8573

Tagged under

Contact Us

Atlas Genetics (USA)
245 First Street
Cambridge

MA 02142
USA

Atlas Genetics (UK)

Derby Court, Epsom Square
White Horse Business Park
Trowbridge, Wiltshire
BA14 0XG
United Kingdom

Find Us

footer logos